Eloxx Pharmaceuticals Stock News

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) posted topline results from the monotherapy arms of its Phase 2 trial of ELX-02 in Class 1 cystic fibrosis patients with at least one G542X nonsense allele mutation. Eloxx delivered one-week ELX-02 data on 12 people with a G542X nonsense mutation who received ELX-02 at 1.5 mg/kg/day. Sweat chloride, a biomarker of cystic fibrosis, Full story available on Benzinga.com

ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity

Eloxx Pharmaceuticals (NASDAQ:ELOX) had its price objective trimmed by HC Wainwright from $3.00 to $2.00 in a research note published on Thursday morning, The Fly reports. The brokerage currently has a neutral rating on the stock. Separately, Zacks Investment Research upgraded Eloxx Pharmaceuticals from a sell rating to a hold rating in a research report []

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights

The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) significantly increased today. This is why it happened.

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)

Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. L

Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021

With July 4th on the way, which penny stocks are you watching right now? The post 7 Reddit Penny Stocks to Watch For the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information

The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) increased by over 7% pre-market. This is why it happened.

Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.

Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.

WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced